Convatec Group Acquires Triad Life Sciences

January 28, 2022

Convatec Group Plc has signed a definitive agreement to acquire Triad Life Sciences Inc, a Memphis-based developer and manufacturer of porcine placenta‑derived extracellular matrix products for advanced wound care. The deal, expected to close in Q1 2022 subject to regulatory approvals, values Triad at an initial $125 million with up to $275 million additional contingent/earnout payments tied to milestones and performance.

Buyers
Convatec Group Plc
Targets
Triad Life Sciences Inc
Sellers
Triad Life Sciences, Inc.
Industry
Medical Devices
Location
Tennessee, United States
Transaction Type
Buyout

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.